Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Stephen P. Mulligan, PhD FRACP, FRCPA, MBBS, Devinder Gill, MD MRCP, FRCPath, Gavin Cull, MB, BS, DM, FRACP, FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Rosemary Anne Harrup, MD, Naomi J. Mackinlay, MB BS, FRACP, FRCPA, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Xavier Badoux, MBBS, AB, FRACP, FRCPA, Oliver Giles Best, PhD BSc, Bryone Jean Kuss, PhD BMBS, FRCPA, FRACP

Blood (2018) 132 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2018-99-114064

Published: 2018

Journal Articles

Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta

Yu-Chen Enya Chen, BSc, Melinda Lea Burgess, Antje Blumenthal, PhD, Sally Mapp, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Devinder Gill, Nicholas Andrew Saunders, PhD

Blood (2018) 132 (Supplement 1): 3128.

https://doi.org/10.1182/blood-2018-99-109719

Published: 2018

Journal Articles

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Carol Moreno, MD PhD, Richard Greil, MD, Fatih Demirkan, MD, Alessandra Tedeschi, MD, Bertrand Anz, MD, Loree Larratt, MD, Martin Simkovic, MD PhD, Olga Samoilova, MD, Jan Novak, MD PhD, Dina Ben-Yehuda, MD, Vladimir Strugov, MD, Devinder Gill, MD MRCP, FRCPath, John G. Gribben, Emily Hsu, PhD, Cathy Zhou, MS, Fong Clow, ScD, Danelle F. James, MD MAS, Lori Styles, MD, Ian W. Flinn, MD PhD

Blood (2018) 132 (Supplement 1): 691.

https://doi.org/10.1182/blood-2018-99-111370

Published: 2018

Journal Articles

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Blood (2018) 132 (Supplement 1): 5565.

https://doi.org/10.1182/blood-2018-99-111369

Published: 2018

Journal Articles

A Critical Role for Intratumoral and Circulating LAG3 in Classical Hodgkin Lymphoma: Analysis from the Rathl Prospective Phase III International Clinical Trial

Blood (2018) 132 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2018-99-112008

Published: 2018

Journal Articles

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

Joshua W.D. Tobin, MD, Jane Royle, MBBS, Robert Mason, MBBS, Millward Michael, Warburton Lydia, Shahneen Sandhu, Andrew Haydon, Georgina Long, Matteo Carlino, Jessica L Smith, Helen Dearden, Peter Mollee, FRACP, FRCPA, MBBS, MMSc, Devinder Gill, MD, Sally Mapp, MD PhD, Victoria Atkinson, Colm Keane, MB, PhD

Blood (2017) 130 (Supplement 1): 5338.

https://doi.org/10.1182/blood.V130.Suppl_1.5338.5338

Published: 2017

Journal Articles

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Blood (2017) 130 (Supplement 1): 1750.

https://doi.org/10.1182/blood.V130.Suppl_1.1750.1750

Published: 2017

Journal Articles

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Suneet Sandhu, MBBS, MPH, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Paul David Turner, MBBS, FRACP, FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MBBS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily Forsyth, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Rosemary Harrup, MBBS, FRACP, FRCPA, Giles Best, BSc, PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone Jean Kuss, PhD MBBS, FRCPA, FRACP, Stephen Mulligan, MBBS, PhD FRACP, FRCPA

Blood (2015) 126 (23): 5295.

https://doi.org/10.1182/blood.V126.23.5295.5295

Published: 2015

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Melinda Burgess, Sally Mapp, MBBS, PhD FRACP, FRCPA, Roberta Mazzieri, PhD, Jonathan Ellis, BSc, MSc, PhD, Catherine Cheung, Lynne Chambers, Stephen Mattarollo, BSc, PhD, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Devinder Gill, MB FRCPath FRACP FRCPA, Nicholas Saunders, BSc, PhD

Blood (2015) 126 (23): 447.

https://doi.org/10.1182/blood.V126.23.447.447

Published: 2015

Journal Articles

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Eric Van Den Neste, MD PhD, Norbert Schmitz, MD, Nicolas Mounier, MD PhD, Devinder Gill, MB FRCPath FRACP FRCPA, Marek Trneny, MD, PhD, Prof., Noel Milpied, John A. Radford, MD, Nicolas Ketterer, Ofer Shpilberg, MD, Ulrich Dührsen, David Ma, MD, Josette Briere, Catherine Thieblemont, Gilles A. Salles, MD PhD, Craig Moskowitz, MD, Bertran Glass, Christian Gisselbrecht

Blood (2015) 126 (23): 517.

https://doi.org/10.1182/blood.V126.23.517.517

Published: 2015

Journal Articles

Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report

Marco Montillo, MD, Susan O'Brien, MD, Alessandra Tedeschi, MD, Peter Hillmen, MB, ChB, PhD, Claire Dearden, MD, Devinder Gill, MD, Jennifer R. Brown, MD PhD, Jaqueline C. Barrientos, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Richard R. Furman, MD, Florence Cymbalista, MD, Clara Plascencia, Stephen Chang, PhD, Emily Hsu, PhD, Danelle F. James, MD MAS, John C. Byrd, MD

Blood (2014) 124 (21): 5654.

https://doi.org/10.1182/blood.V124.21.5654.5654

Published: 2014

Journal Articles

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS, FRACP, FRCPA, Leanne Berkahn, MD, David R Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 4695.

https://doi.org/10.1182/blood.V124.21.4695.4695

Published: 2014

Journal Articles

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 4696.

https://doi.org/10.1182/blood.V124.21.4696.4696

Published: 2014

Journal Articles

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Paul Turner, MBBS FRACP FRCPA, William E. P. Renwick, MBBS, FRACP, FRCPA, Maya Latimer, MBBS, FRACP, FRCPA, Naomi Mackinlay, MB BS FRACP FRCPA, Leanne Berkahn, MD, David Simpson, MBChB, FRACP, FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Cecily J Forsyth, MB BS, FRACP, FRCPA, Gavin Cull, MBBS, DM, FRACP, FRCPA, Rosemary Harrup, MB BS, FRACP, FRCPA, Melanie Sulda, B.Sc, PhD, Giles Best, BSc (Hons), PhD, Mathias Bressel, MSc, Juliana Di Iulio, BAppSc, PhD, Bryone J Kuss, MBBS, PhD FRCPA, FRACP

Blood (2014) 124 (21): 3325.

https://doi.org/10.1182/blood.V124.21.3325.3325

Published: 2014

Journal Articles

Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes

Kyaw Zeya Maung, BSc, James X Gray, MD PhD, Paul J Leo, PhD, Mahmoud Bassal, BSc, Anna L Brown, PhD, Sarah C Bray, PhD, Ing Soo Tiong, MBChB, Chung H Kok, PhD, Andrew Deans, PhD, Mhairi Marshall, PhD, Brooke Gardiner, PhD, Evgeny A Glazov, PhD, Paula Marlton, MBBS, Devinder Gill, MD, Luen Bik To, MBBS, PhD, Ian D Lewis, MBBS, PhD, Richard J D'Andrea, PhD, Thomas J Gonda, PhD

Blood (2014) 124 (21): 698.

https://doi.org/10.1182/blood.V124.21.698.698

Published: 2014

Journal Articles

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

Maher K Gandhi, PhD, FRACP, FRCPath, FRCP, Frank Vari, Phd, Pauline Crooks, Colm Keane, MB BCh BAO MSc MRCPI FRCPath, Jamie P Nourse, PhD, Louise A Seymour, MBBS, FRCPA, David Ritchie, MB, PhD, FRACP, FRCPA, David Gottlieb, MB, PhD, FRCPA, FRACP, Devinder Gill, MB, FRCPath, FRACP, FRCPA, Kimberley Jones, BSc

Blood (2012) 120 (21): 49.

https://doi.org/10.1182/blood.V120.21.49.49

Published: 2012

Journal Articles

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaemia (AML).

James X Gray, MD, PhD, Lyle McMillen, PhD, Russell Saal, MMedSc, Steven Lane, MBBS, Peter Mollee, MBBS, Robert Bird, MBBS, Devinder Gill, MBChB, Paula Marlton, MBBS

Blood (2009) 114 (22): 2639.

https://doi.org/10.1182/blood.V114.22.2639.2639

Published: 2009

Journal Articles

Treatment of Acute Promyelocytic Leukaemia in Jehovah’s Witness(JW) Population

Colm G Keane, MB, BCH, BAO, MRCPI, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Paula Marlton, MBBS, FRCPA, FRACP, Devinder Gill, MD

Blood (2008) 112 (11): 4014.

https://doi.org/10.1182/blood.V112.11.4014.4014

Published: 2008

Journal Articles

Identification of Two Novel Chemokines (CCL2 and CXCL2) in B-Chronic Lymphocytic Leukaemia (B-CLL) and Prolonged Survival of Primary B-CLL Cells in Vitro

Devinder Gill, MB, FRCPath, FRACP, FRCPA, Melinda Burgess, Louise Knop, BSc, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Nigel McMillan, PhD

Blood (2008) 112 (11): 3157.

https://doi.org/10.1182/blood.V112.11.3157.3157

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Durable Responses in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) in a Randomised, Fludarabine-Based, Immunochemotherapy Dose De-Escalation Study - Long-Term Follow-up By Treatment Arm and Mutational Status

Activation of Fc Gamma Receptor-Dependent Responses to Therapeutic Antibodies By Nurse like Cells Requires PI3Kdelta

Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

A Critical Role for Intratumoral and Circulating LAG3 in Classical Hodgkin Lymphoma: Analysis from the Rathl Prospective Phase III International Clinical Trial

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

Single-Agent Ibrutinib Vs Chemoimmunotherapy Regimens for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia (CLL): A Cross-Trial Comparison

Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial

Emergence of Fc-Gamma-Riib-Dominance Contributes to Resistance to Therapeutic Antibodies in Patients with Chronic Lymphocytic Leukaemia

Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study

Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report

Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL)

Hematologic and Immunologic Function and Patient Well-Being for the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity

Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

WT1 Expression Levels at Diagnosis and as a Marker of Minimal Residual Disease (MRD) in Patients with Acute Myeloid Leukaemia (AML).

Treatment of Acute Promyelocytic Leukaemia in Jehovah’s Witness(JW) Population

Identification of Two Novel Chemokines (CCL2 and CXCL2) in B-Chronic Lymphocytic Leukaemia (B-CLL) and Prolonged Survival of Primary B-CLL Cells in Vitro

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only